Arcellx Inc Share Price & Technical Analysis
ACLX · $115.1 (+0.02%)
Healthcare / Biotechnology
$115.1
+0.02%
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a produ…
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
74% return in 2026, 42% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 5% | 68% | 1% | 0% | – | – | – | – | – | – | – | – | 74% |
| 25 | -11% | -2% | 1% | -1% | -3% | 6% | 9% | -2% | 21% | 12% | -19% | -9% | 1% |
| 24 | 13% | 5% | 5% | -28% | 3% | 5% | 13% | 13% | 22% | 3% | 4% | -13% | 45% |
| 23 | 7% | -16% | 10% | 40% | 4% | -28% | 9% | 5% | 0% | -2% | 48% | 6% | 81% |
| 22 | – | 1% | -27% | -22% | 13% | 52% | 15% | -10% | 7% | 24% | -16% | 56% | 92% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. As of April 28, 2026, Arcellx, Inc. operates as a subsidiary of Gilead Sciences, Inc.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.73B
P/E ratio
—
52W high
$115.1
52W low
$50.85
Volume
1,31,91,486
Beta
0.25
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Arcellx Inc share price today?
- Arcellx Inc (ACLX) last traded around $115.1 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ACLX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ACLX. Download the app for real-time alerts.
- How can I analyze Arcellx Inc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.